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responsibility of XAbstract Bergenin, a C-glucoside of 4-O-methyl gallic acid from Bergenia purpurascens, is a
naturally antitussive and expectorant agent. A rapid and sensitive liquid chromatography tandem
mass spectrometry (LC–MS/MS) method has been developed and validated for the determination
of the active component—bergenin, in rat plasma after oral administration of aqueous
B. purpurascens extract. The plasma samples were pretreated by protein precipitation with
acetonitrile and chromatographic separation was achieved on a Diamonsils C18 column
(150 mm 4.6 mm, 5 mm) with isocratic elution using a mobile phase consisting of water–
methanol (30:70, v/v) at a ﬂow rate of 0.6 mL/min. The detection was accomplished by a triple-
quadrupole tandem mass spectrometer in multiple-reaction monitoring (MRM) scanning via an
electrospray ionization (ESI) source operating in the negative mode. The optimized mass transition
ion-pairs (m/z) for quantitation were 327.3/192.0 for bergenin, and 431.1/311.1 for IS. The time for
each analysis run was only 3.5 min between injections. The calibration curve exhibited good
linearity (r240.99) over a range of 1.00–2000 ng/mL for bergenin. The lower limit of quantitation
(LLOQ) was 1.00 ng/mL. The intra- and inter-day precisions were no more than 11.8%, and
relative errors (RE) were within the range of 0.0–4.4%. The validated method was successfully
applied to investigate the pharmacokinetics of bergenin after oral administration of B. purpurascens
extract in rats.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.ersity. Production and hosting by E
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22896555.
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i’an Jiaotong University. 1. Introduction
Yanbaicai, the rhizome of Bergenia purpurascens, is a well-known
and widely used traditional Chinese medicine (TCM) for relief
against cough and asthma in Chinese folk [1,2]. Biological andlsevier B.V. All rights reserved.
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extract showed antioxidant, anti-inﬂammatory and immunologic
enhancement activities [3–5]. Phytochemical investigation indi-
cated that more than 20 compounds had been identiﬁed from
the plant B. purpurascens, in which bergenin was the principal
compound contributing to the biological activity [6–9]. Bergenin, a
C-glucoside of 4-O-methyl gallic acid isolated from B. purpur-
ascens has a variety of pharmacological activities, including
antiarrhythmic, antihepatotoxic, antiulcerogenic, anti-inﬂamma-
tory, anti-HIV, antimicrobial, immunomodulatory and neuropro-
tective properties [10–13]. To date, there is no report about the
pharmacokinetics of the B. purpurascens extract in vivo, even
though several reports for pharmacokinetics have estimated the
concentration of bergenin after oral administration of bergenin
tablets by LC–MS/MS [14,15]. Compared with the published
papers [14,15], in the present study, we have developed a much
more sensitive (LLOQ, 1.00 ng/mL) and rapid (running time,
3.5 min) LC–MS/MS method to measure bergenin in rat
plasma for the ﬁrst time after oral administration of aqueous B.
purpurascens extract.2. Materials and methods
2.1. Chemicals and reagents
Bergenin (purity499.0%, determined by HPLC) was isolated
from B. purpurascens in our laboratory. The structure of
bergenin (Fig. 1A) was fully characterized by 1H, 13C NMR
and MS data (seeing the supporting information, Table S1).
Isovitexin (purity498%, determined by HPLC, Fig. 1B) was
used as an internal standard (IS), which was isolated from the
leaves of Santalum album L. and characterized by NMR
technique (seeing the supporting information, Table S1).
HPLC-grade methanol and acetonitrile were purchased from
Merck (Darmstadt, Germany). Deionized water was prepared
by a Milli-Q system (Millipore, MA, USA).2.2. Instrumentation
An Agilent 1200 LC system consisting of a degasser, a binary
pump, an SL autosampler and a thermostatic column com-
partment was coupled with a 6410 triple-quadrupole mass
spectrometer (Agilent Technologies, USA), which was
equipped with an electrospray ionization (ESI) source and
operated with Agilent MassHunter B.01.03 software (Agilent
Technologies, USA).Fig. 1 Chemical structure of b2.3. Chromatographic and mass spectrometric conditions
Chromatographic separation was performed on a Diamonsils
C18 column (150 mm 4.6 mm, 5 mm; Beijing, China) protected
by a Phenomenex C18 guard column (Torrance, CA, USA).
The mobile phase consisted of water (A) and methanol (B) using
an isocratic elution with a mixture of 30 volumes of solvent A
and 70 volumes of solvent B. The ﬂow rate was 0.6 mL/min, and
the injection volume was 20 mL. The time for each analysis run
was only 3.5 min, and a divert valve was used to divert the eluent
to waste from 0 to 1.9 min, and to MS from 1.9 min to 3.5 min.
The mass spectrometer was operated in negative ESI scan
mode for bergenin. Quantiﬁcation was obtained using multiple-
reaction monitoring (MRM) transition, which was selected as
m/z 327.3-m/z 192.0 for bergenin and m/z 431.1-m/z 311.1
for IS (Fig. 2). MS/MS conditions were optimized as follows:
gas temperature, 300 1C; gas ﬂow, 10 L/min; nebulizer, 30 psi;
collision gas (N2), 0.35 Pa. The fragment energy was set at
110 V and 160 V for the analyte and IS, respectively. The
collision energy was optimized to be 15 eV and 18 eV for the
analyte and IS, respectively.2.4. Preparation of B. purpurascens extract
Ten grams B. purpurascens shattered into powder was extracted
three times with 50% ethanol under reﬂux. After the removal of
the major solvent in vacuum, the aqueous residue was then diluted
with water to get the B. purpurascens extract with a concentration
equivalent to 1.58 g/mL of the raw B. purpurascens material.
To calculate the administration dose, the content of
bergenin in aqueous B. purpurascens extract was quantitatively
determined using the LC–MS/MS method described above.
The content of bergenin in the extract was 16.3 mg/mL.2.5. Preparation of standard and quality control (QC)
samples
Standard stock solution of 100 mg/mL bergenin was accurately
prepared by dissolving appropriate amounts of the standard in
acetonitrile. A 1000 ng/mL isovitexin solution as IS was also
prepared in acetonitrile. All solutions were stored at 4 1C.
Calibration standards were prepared by spiking appropriate
amount of the standard solutions in 100 mL of blank rat
plasma to yield ﬁnal concentrations of 1.00, 3.00, 10.0, 30.0,
100, 300, 1000, and 2000 ng/mL for bergenin. Three concen-
tration levels of QC samples were prepared containing
bergenin (3.00, 30.0, 1800 ng/mL) in the same manner.ergenin and isovitexin (IS).
Fig. 2 MS and MS/MS spectra of (A) [M–H]– at m/z 327.3 of bergenin and (B) [M–H]– at m/z 431.1 of isovitexin (IS).
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100 mL of rat plasma samples (Calibration standards, QC
samples, and pharmacokinetic plasma samples) was mixed
with 100 mL of acetonitrile and 100 mL of IS working solution.
The mixture was vortexed for 1 min and then centrifuged at
10,000 rpm for 5 min. Then about 100 mL of the supernatant
was transferred to the autosampler vials ready for injection
into the LC–MS/MS system.2.7. Method validation
The method performance was validated according to the FDA
recommendations proposed in 2001 [16,17]. Several validation
characteristics were investigated, such as selectivity, linearity,
lower limit of quantiﬁcation (LLOQ), precision, accuracy,
matrix effect, extraction recovery and stability.2.8. Pharmacokinetic study
Six male Wistar rats (200720 g) were purchased from the
Experimental Animal Center of Guangdong Medical College
(Dongguan, China). The rats were housed in an air-
conditioned room at temperature of 2272 1C and a relative
humidity of 50710% with a 12 h dark–light cycle and allowed
food and water spontaneously. Rats were fasted for 12 h
before the experiment with water freely available.After an oral administration of aqueous B. purpurascens
extract at a dose of 6 mL/kg (equivalent 97.8 mg bergenin/kg
body weight), blood samples were harvested into 1.5 mL
heparinized eppendorf tubes from each rat via the orbital vein
before dosing and at 0.083, 0.25, 0.50, 0.75, 1.0, 1.5, 2.0, 3.0, 5.0,
8.0, 12.0 and 24.0 h. After centrifugation at 3000 rpm/min for
10 min, plasma samples were transferred to neat tubes and stored
at 20 1C until analysis. All pharmacokinetic parameters were
evaluated by noncompartmental analysis using DAS 2.0 software
(Chinese Pharmacological Society, China).3. Results and discussion
3.1. Method development
In the preliminary experiment the ESI and atmospheric
pressure chemical ionization (APCI) sources were chosen to
obtain good and stable MS response. Bergenin and IS could
be ionized under negative ESI or APCI conditions. It was
found that ESI can provide higher sensitivity for the analyte
and IS than that of APCI.
Different chromatographic conditions, especially the composi-
tion of mobile phase, were assessed to achieve good resolution
and strong MS intensity, as well as short run time. Various
combinations of acetonitrile, methanol and water were tested
and compared to identify the appropriate mobile phase. As a
result, a mixture consisting of water and methanol (30:70, v/v)
Fig. 3 Typical MRM chromatograms of bergenin and isovitexin (IS) in rat plasma: (A) blank plasma; (B) plasma spiked with bergenin
at 1.00 ng/mL and I.S. at 1000 ng/mL; (C) plasma spiked with bergenin at 2000 ng/mL and and I.S. at 1000 ng/mL; and (D) plasma at
0.75 h after oral administration of aqueous Bergenia purpurascens extract. Peaks I and II refer to IS and bergenin, respectively.
Table 1 Precision and accuracy of the LC–MS/MS assay for bergenin in rat plasma using isovitexin as IS (method validation for
3 days, mean7SD, n¼6 for per day).
Added (ng/mL) Found (ng/mL) Precision (RSD%) Accuracy (RE%)
Intra-day Inter-day
3.00 3.0070.15 5.4 0.6 0.0
30.0 31.071.2 4.0 3.4 3.5
1800 18787124 4.0 11.8 4.4
Table 2 Extraction recoveries and matrix effects of bergenin in rat plasma (n¼3).
Added (ng/mL) Extraction recovery (%, average7SD) Matrix effect (%, average7SD)
Bergenin
3.00 100.572.7 102.170.8
30.0 99.372.6 –
1800 99.175.6 99.073.2
Isovitexin (IS)
1000 101.371.9 105.172.3
B.-H. Li et al.232was ﬁnally adopted as the mobile phase. Flow rate of 0.6 mL/min
produced good peak shapes and short run time (3.5 min).3.2. Assay validation
3.2.1. Selectivity
Under the chromatographic conditions described above, ber-
genin and IS were eluted at 2.62 and 2.68 min (Fig. 3),
respectively. No obvious interfering endogenous substances
were observed at the retention times of bergenin and IS in
blank plasma sample.3.2.2. Linearity and LLOQ
The linear regressions of the peak area ratios versus concentra-
tions were ﬁtted over the concentration range 1.00–2000 ng/mL
for bergenin in rat plasma. A typical equation of the calibration
curve was y¼3.9781 105xþ6.1424 105, r2¼0.9936, where
y represents the ratio of bergenin peak area to that of IS and x
represents the plasma concentration. The LLOQ of bergenin in
plasma was 1.00 ng/mL. The present method exhibited a good
linearity and sensitivity.
3.2.3. Precision and accuracy
The intra- and inter-day precision and accuracy of bergenin
are summarized in Table 1. In the present assay, the intra- and
Table 3 Stability of bergenin in rat plasma in various conditions (n¼3).
Stability Accuracy (average7SD; ng/mL )
3.00 ng/mL 1800 ng/mL
Short-term stability (at ambient condition for 2 h) 2.8770.11 1894766
Post preparative stability (in the autosampler at ambient condition for 12 h) 3.0370.15 1835763
Freeze–thaw stability (three cycles) 3.2270.19 1911741
Long-term stability (at 20 1C for 30 days) 2.9870.22 1782793
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Fig. 4 Mean plasma concentration–time proﬁle of bergenin after oral administration of aqueous Bergenia purpurascens extract.
Table 4 Pharmacokinetic parameters of bergenin in rats
after oral administration of Bergenia purpurascens extract
(n¼6).
Pharmacokinetic parameters Average7SD
Cmax (ng/mL) 2757164
Tmax (h) 0.29270.102
t1/2 (h) 8.0373.24
AUC0–t (ng h/mL) 5487408
AUC0–N (ng h/mL) 5887412
MRT0–t (h) 4.9970.66
MRT0–N (h) 7.6772.10
LC–MS/MS determination and pharmacokinetic study of bergenin 233inter-day precision (RSD) were within 5.4% and 11.8%, respec-
tively; the accuracy did not exceed 4.4%. The obtained data were
within acceptable criteria and conformed to the guidelines for
bioanalytical method validation [16], which indicated that the
present method was reproducible and reliable for the determina-
tion of bergenin in rat plasma samples.
3.2.4. Matrix effect (ME)
The MEs for bergenin at concentrations of 3.00 and 1800 ng/mL
were measured to be 102.170.8% and 99.073.2% (n¼3),
respectively. The ME for IS was 105.172.3% (n¼3). As a
result, the ME from plasma was negligible in this method
(Table 2).
3.2.5. Extraction recovery
The extraction recoveries of bergenin at three QC levels (3.00,
30.0, 1800 ng/mL) were determined by comparing the peak
area of the analyte to which the analyte was added post-
protein precipitation at equivalent concentrations. The recov-
ery of the IS (1000 ng/mL) was determined in a similar way.
At three concentration levels of the analyte, the recoveries
were between 99.175.6% and 100.572.7% (Table 2).
3.2.6. Stability
The freeze–thaw stability was determined after three freeze–
thaw cycles at 20 1C with a minimal interval of 24 h.
The long-term stability was evaluated by analyzing samples
kept at 20 1C for 30 days. The short-term stability was
assessed after keeping the samples at ambient condition for
2 h. Post-preparative stability was evaluated by analyzingpost-protein precipitation samples kept in the autosampler at
ambient condition for 12 h. The results of the stability study
are presented in Table 3, which conﬁrm the high stability of
bergenin throughout the determination.3.3. Pharmacokinetics application
After oral administration of B. purpurascens extract at a dose
of 6 mL/kg (equivalent 97.8 mg bergenin/kg body weight) to
six Wistar rats, their plasma concentration of bergenin was
determined by the described LC–MS/MS method. The mean
plasma concentration–time proﬁle is represented in Fig. 4 and
the main pharmacokinetic parameters are listed in Table 4.
Plasma concentration of bergenin was detectable as early as
10 min after administration, with a mean peak concentration
B.-H. Li et al.234in plasma (Cmax) of 2757164 ng/mL and the time to peak
(Tmax) of 0.29270.102 h. The elimination half life (t1/2), mean
residence time (MRT) and area under the concentration–time
curve from time 0 to 24 h (AUC0–24) were 8.0373.24 h,
4.9970.66 h and 5487408 ng h/mL, respectively.4. Conclusion
In general, a rapid and sensitive LC–MS/MS method was
developed and validated for the determination of bergenin in
rat plasma after oral administration of B. purpurascens extract.
The pharmacokinetics obtained from this study and the
method developed herein might provide useful information
for clinical application of this TCM.
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